Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, and its news flow reflects both internal pipeline progress and partner-driven milestones. The company regularly issues updates on its XmAb® drug candidates, including T-cell engaging bispecific antibodies and Fc-engineered antibodies that use its XmAb and Xtend™ technologies.
Investors following XNCR news can expect detailed announcements on clinical trial progress across oncology and autoimmune indications. Recent releases have covered Phase 1 and Phase 2 studies of programs such as XmAb819 for advanced clear cell renal cell carcinoma, XmAb541 for gynecologic and germ cell tumors, plamotamab for rheumatoid arthritis, XmAb657 for idiopathic inflammatory myopathies, and XmAb942 and XmAb412 for inflammatory bowel and other autoimmune diseases. These updates often include safety and efficacy summaries, dose-escalation status, and plans for pivotal or proof-of-concept studies.
Xencor’s news stream also features financial results and guidance, including quarterly earnings, cash and marketable securities levels, and commentary on how its balance sheet supports research and development plans. In addition, the company reports on intellectual property developments, such as U.S. patent issuances that extend royalty terms on Xtend-based antibodies like Ultomiris, and on collaboration milestones with partners including Amgen, Astellas, Incyte and Zenas Biopharma.
Corporate governance and strategic updates, such as board appointments and participation in investor conferences, are also common topics. For investors and analysts, the XNCR news page provides a centralized view of how Xencor’s XmAb technology platform is progressing in the clinic, how partnered programs are advancing, and how these activities translate into milestones, royalties and long-term development plans.
Xencor (NASDAQ: XNCR) has announced preclinical data on XmAb942, a high-potency, extended half-life anti-TL1A antibody for inflammatory bowel diseases. The data will be presented at UEG Week in Vienna. XmAb942 aims to be a best-in-class next-generation anti-TL1A antibody, offering superior potency and less frequent dosing compared to first-generation antibodies.
Key points:
- First subject dosing in Phase 1 healthy volunteer study expected in Q4 2024
- Initial data from single-ascending dose portion anticipated in H1 2025
- Preclinical data shows comparable or superior in vitro potency to first-generation anti-TL1A antibodies
- 23-day half-life in non-human primates, potentially supporting 8-12 week dosing in humans
Xencor (NASDAQ: XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and other serious diseases, has announced an upcoming change to its Board of Directors. Dagmar Rosa-Bjorkeson, who has served as a director since 2019, will not seek reelection at the 2025 Annual Meeting of Stockholders. Rosa-Bjorkeson plans to pursue another business opportunity.
Xencor is actively recruiting additional Board members with complementary skillsets. The company's CEO, Bassil Dahiyat, Ph.D., expressed gratitude for Rosa-Bjorkeson's contributions to the Board and its audit and nominating and governance committees, particularly her strategic guidance in advancing programs and rebalancing the company's portfolio.
Xencor (XNCR) has successfully closed its public offering, raising approximately $201.3 million in gross proceeds. The offering included 8,093,712 shares of common stock at $18.00 per share and 3,088,888 pre-funded warrants at $17.99 each. The underwriters fully exercised their option to purchase additional shares. Xencor plans to use the net proceeds for general corporate purposes, including research and development, capital expenditures, and working capital. The offering was made through an automatic shelf registration statement, with Leerink Partners, Raymond James, and RBC Capital Markets acting as joint book-running managers.
Xencor (XNCR) has priced its public offering of common stock and pre-funded warrants, aiming to raise $175 million. The offering includes 6,635,112 shares at $18.00 per share and 3,088,888 pre-funded warrants at $17.99 each. Underwriters have a 30-day option to purchase up to 1,458,600 additional shares. The clinical-stage biopharmaceutical company plans to use the proceeds for general corporate purposes, including research and development, capital expenditures, and working capital. The offering is expected to close around September 12, 2024, subject to customary conditions.
Xencor (Nasdaq: XNCR), a clinical-stage biopharmaceutical company, has announced a proposed public offering of common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase up to an additional 15% of shares. Leerink Partners, Raymond James, and RBC Capital Markets are acting as joint book-running managers, with Wedbush PacGrow as co-manager.
The company plans to use the net proceeds for general corporate purposes, including research and development, capital expenditures, and working capital. The offering is being made through an automatic shelf registration statement on Form S-3, with a preliminary prospectus supplement to be filed with the SEC.
Xencor, Inc. (NASDAQ: XNCR) announced four new XmAb® programs for treating autoimmune diseases and provided updates on early-stage oncology programs. Key highlights include:
1. XmAb942: Phase 1 study for IBD to start Q4 2024, with data expected H1 2025.
2. Plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3): To be evaluated for autoimmune diseases, with studies starting in 2025.
3. XmAb819 (ENPP3 x CD3): Showing encouraging clinical activity in advanced clear cell renal cell carcinoma.
4. XmAb808 (B7-H3 x CD28): Demonstrating PSA declines in metastatic castration-resistant prostate cancer patients.
The company aims to leverage its protein engineering strengths to increase clinical success opportunities.
Xencor (NASDAQ: XNCR), a clinical-stage biopharmaceutical company, has announced a Research & Development Webcast and Conference Call scheduled for Monday, September 9, 2024, at 8:00 a.m. ET. The event will introduce new XmAb® programs for treating autoimmune diseases and provide updates on oncology programs, including:
- XmAb819 (ENPP3 x CD3) for advanced clear cell renal cell carcinoma
- XmAb808 (B7-H3 x CD28) for advanced solid tumors
The webcast can be accessed through the Investors section of Xencor's website. A recording will be available for at least 30 days after the event.
Xencor (NASDAQ:XNCR) reported Q2 2024 financial results and provided updates on its clinical-stage programs. Key highlights include:
- Cash position of $585.0 million as of June 30, 2024
- Q2 2024 revenues of $17.0 million, down from $45.5 million in Q2 2023
- Net loss of $66.0 million ($1.07 per share) in Q2 2024
- Advancing clinical trials for XmAb819, XmAb808, and XmAb541
- Regained worldwide rights to plamotamab
- Expects to end 2024 with $475-$525 million in cash, funding operations into 2027
The company continues to focus on developing bispecific T-cell engagers and other XmAb candidates, with plans to announce new clinical development candidates in the coming months.
Xencor (NASDAQ: XNCR) announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen Biotech terminated its rights under their collaboration agreement. Xencor had advanced plamotamab through Phase 1 clinical trials targeting hematologic cancers. Despite Janssen's withdrawal, it retains rights to develop and commercialize other B-cell targeting CD28 bispecific antibodies, JNJ-9401 and JNJ-1493, which are in Phase 1 clinical trials for prostate cancer and B-cell malignancies respectively.
Xencor emphasizes that plamotamab is Phase 2 ready and subcutaneously administered, highlighting its potential to address unmet medical needs. The company remains eligible for milestone payments and royalties from Janssen's ongoing projects and has the option to co-fund development costs for increased royalty benefits.
Xencor, a clinical-stage biopharmaceutical company, reported financial results for the first quarter ended March 31, 2024, focusing on bispecific T cell engagers for cancer treatment. Recent highlights include the advancement of multiple oncology programs, FDA approval of Ultomiris, and positive results in malaria prevention. The company appointed a new CFO and provided financial guidance with a cash balance of $646.7 million as of March 31, 2024. Despite a decrease in revenues and an increased net loss compared to the previous year, Xencor remains well-funded.